TABLE 2.
Clinical and pathological characteristics of cervical cancer patients participating in the study
| Stage and category | na | Gene ratios and P valuesb
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
L1/E6
|
E1/E6
|
E2/E6
|
E1/E2
|
E2/(E1*E6)
|
|||||||||||||
| Low | High | P | Low | High | P | Low | High | P | Low | High | P | Low | Medium | High | P | ||
| FIGO stage | |||||||||||||||||
| 0 | 7 | 4 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 2 | 4 | 1 | |||||
| I (IA + IB) | 29 (3 + 26) | 22 | 7 | 0.47 | 18 | 11 | 0.38 | 17 | 12 | 0.02 | 22 | 7 | 0.09 | 16 | 8 | 5 | 0.001 |
| II (IIA + IIB + IIIB) | 30 (17 + 10 + 3) | 19 | 11 | 23 | 7 | 26 | 4 | 25 | 5 | 26 | 3 | 1 | |||||
| Histopathology | |||||||||||||||||
| Squamous cell carcinoma | |||||||||||||||||
| In situ | 14 | 8 | 6 | 8 | 6 | 6 | 8 | 9 | 5 | 5 | 6 | 3 | |||||
| Keratinizing | 5 | 3 | 2 | 0.65 | 4 | 1 | 0.65 | 4 | 1 | 0.01 | 3 | 2 | 0.01 | 4 | 0 | 1 | 0.005 |
| Nonkeratinizing | 46 | 33 | 13 | 32 | 14 | 35 | 11 | 39 | 7 | 35 | 9 | 2 | |||||
| Adenosquamous cell carcinoma | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | |||||
| Histopathology lymph nodes | |||||||||||||||||
| Nonmetastatic | 37 | 27 | 10 | 0.34 | 26 | 11 | 0.68 | 25 | 12 | 0.67 | 27 | 10 | 0.34 | 22 | 10 | 5 | 0.68 |
| Metastatic | 29 | 18 | 11 | 19 | 10 | 21 | 8 | 24 | 5 | 19 | 8 | 2 | |||||
a
n = numbers of cases in a given category or subcategory.
b
Cluster analysis of investigated HPV gene ratios in different clinical and histopathological groups of patients was performed. Two significantly different clusters were obtained for each ratio except for the E2/(E1*E6) ratio, where three clusters were found. The values of P were calculated as a chi-square test probability. P values apply to all values within the specified category.